Source link : https://www.newshealth.biz/health-news/novel-bispecific-in-egfr-mutant-lung-cancer-boosts-pfs-after-targeted-agents/
CHICAGO — An investigational bispecific antibody targeting PD-1 and VEGF significantly decreased the risk of disease progression or death in patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC) who progressed on targeted agents, a randomized study from China showed. In primary results of the HARMONi-A trial, median progression-free survival (PFS) improved from 4.8 months […]
Author : News Health
Publish date : 2024-06-01 20:56:08
Copyright for syndicated content belongs to the linked Source.
Categories